44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617

EJNMMI Research

Volumn 7, Issue 1, 2017, Pages

  Umbricht, Christoph A ^a   Benešová, Martina ^a,b   Schmid, Raffaella M ^a   Türler, Andreas ^c,d   Schibli, Roger ^a,b   van der Meulen, Nicholas P ^a,c   Müller, Cristina ^a,b  

^a ETH Zurich   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c PAUL SCHERRER INSTITUTE   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

177Lu; 44Sc; 68Ga; Cyclotron; PET imaging; Prostate cancer; PSMA; Theragnostics

Indexed keywords

GALLIUM 68; LUTETIUM 177; RADIOLIGAND; SCANDIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOLOGICAL PROCEDURES; RADIOTHERAGNOSTICS;

EID: 85010053601     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/s13550-017-0257-4     Document Type: Article

References (40)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254.
2. Chu KC, Tarone RE, Freeman HP. Trends in prostate cancer mortality among black men and white men in the United States. Cancer. 2003;97(6):1507–16. doi:10.1002/cncr.11212.
3. Turkbey B, Pinto PA, Choyke PL. Imaging techniques for prostate cancer: implications for focal therapy. Nature Rev Urol. 2009;6:191–203.
4. Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol. 2013;31(4):427–35. doi:10.1016/j.urolonc.2010.08.008.
5. 99mTc-MDP bone imaging semi-quantitative analysis in differential diagnosis of benign and malignant lesions in the prostate cancer patients. J Nucl Med. 2016;57(no. supplement 2):1768.
6. Tombal B, Lecouvet F. Modern detection of prostate cancer’s bone metastasis: is the bone scan era over? Adv Urol. 2012;2012:893193. doi:10.1155/2012/893193.
7. 18F-Fluorocholine. Am J Nucl Med Mol Imaging. 2015;5(2):96–108.
8. Bouchelouche K, Choyke PL, Capala J. Prostate specific membrane antigen—a target for imaging and therapy with radionuclides. Discov Med. 2010;9(44):55–61.
9. Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. QJ Nucl Med Imaging. 2015;59(3):241–68.
10. Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M. New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res. 2016;22(1). doi:10.1158/1078-0432.CCR-15-0820.
11. Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.
12. Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005;11:4022–8.
13. Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69(17):6932–40. doi:10.1158/0008-5472.CAN-09-1682.
14. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53:5333–41.
15. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23(4):688–97. doi:10.1021/bc200279b.
16. 68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel). 2014;7(7):779–96. doi:10.3390/ph7070779.
17. 68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016;43:34–41.
18. 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;42:197–209.
19. 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668–74.
20. Benesova M, Schäfer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56(6):914–20. doi:10.2967/jnumed.114.147413.
21. Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705.
22. 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;36(5).
23. 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43(9):1611–20. doi:10.1007/s00259-016-3419-0.
24. 18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17(4):565–74.
25. 18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016;43(10):1929–30. doi:10.1007/s00259-016-3447-9.
26. 44Sc. Appl Radiat Isot. 2016;109:314–8. doi:10.1016/j.apradiso.2015.12.007.
27. 44Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET. Appl Radiat Isot. 2016;110:129–33. doi:10.1016/j.apradiso.2016.01.006.
28. 44Sc for labelng of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations. EJNMMI Radiopharm Chem. 2016;1:8.
29. 44Sc: from bench to bedside. Nucl Med Biol 2015;42:745–51.
30. 44Sc generator system. Curr Radiopharm. 2012;5(3):187–201.
31. Müller C, Mindt TL, de Jong M, Schibli R. Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy. Eur J Nucl Med Mol Imaging. 2009;36(6):938–46. doi:10.1007/s00259-008-1058-9.
32. Banerjee SR, Ngen EJ, Rotz MW, Kakkad S, Lisok A, Pracitto R, et al. Synthesis and evaluation of Gd(III)-based magnetic resonance contrast agents for molecular imaging of prostate-specific membrane antigen. Angew Chem Int Ed Engl. 2015;54(37):10778–82. doi:10.1002/anie.201503417.
33. 64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem. 2014;57(6):2657–69. doi:10.1021/jm401921j.
34. Majkowska-Pilip A, Bilewicz A. Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals. J Inorg Biochem. 2011;105(2):313–20. doi:10.1016/j.jinorgbio.2010.11.003.
35. 44Sc-DOTA-folate conjugate. J Nucl Med. 2013;54(12):2168–74. doi:10.2967/jnumed.113.123810.
36. 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39(3):501–11. doi:10.1007/s00259-011-2003-x.
37. 177Lu-labeled PSMA-617: initial experience in prostate cancer patients. Nucl Med Biol. 2016;43(5):296–302. doi:10.1016/j.nucmedbio.2016.02.002.
38. 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016;41(7):522–8. doi:10.1097/RLU.0000000000001240.
39. 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(1):42–51. doi:10.1007/s00259-015-3174-7.
40. 68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17:575–84.